Monday

My comments on low vaccine efficacy 'misinterpreted" - Chinese official


CC™ Global News

China's top infectious disease control official said his comments on the effectiveness of his country's vaccines over the weekend were misinterpreted.

The director of the Chinese Centre for Disease Control and Prevention, Gao Fu, said it was a "complete misunderstanding'' that he had said Chinese vaccines offer a low level of protection, in comments to state newspaper the Global Times on Monday.

He had been presenting a "scientific vision'' that adapting vaccine sequences or administering different jabs on after the other could also be options for increasing protection, he said.

"The protection rates of all vaccines in the world are sometimes high, and sometimes low. How to improve their efficacy is a question that needs to be considered by scientists around the world,'' Gao said.

Gao Fu was talking at a conference in Chengdu on Saturday on the topic of how to solve the insufficient protection of current vaccines, Chinese news outlet Pengpai Xinwen (The Paper) reported.

"It is also necessary to consider ways to address the low protection rate of existing vaccines,'' he was cited as saying.

His comments prompted a reaction because there is far less data available on Chinese vaccines than those being produced in many other countries.

Critics have complained of a lack of transparency when it comes to Chinese jabs, which have not been authorized in many European nations.

Data from the third phase of clinical studies was particularly sought after.

Because China has the Coronavirus pandemic largely under control and was reporting hardly any local infections, studies so far have only been published from other countries where vaccines were being used.


WORLD PRESS

Sunday

52 Nigerians hit with severe reactions after taking AstraZeneca vaccine

CC™ Medical News

The National Primary Health Care Development Agency, NPHCDA, on Friday disclosed that 52 Nigerians have experienced moderate to severe reactions after taking the AstraZeneca vaccine.

Executive Director and Chief Executive Officer, NPHCDA, Dr. Faisal Shuaib disclosed this at a news conference in Abuja.

He also said 8,439 Nigerians experienced mild Adverse events following immunization (AEFI) after taking the vaccine.

Shuaib stated that the 52 Nigerians that experienced moderate to severe reactions to the vaccine were brought down with fever, vomiting, diarrhea headaches, dizziness and allergic reactions

“In Nigeria, since the vaccination program was officially rolled out on 15th of April 2021, a total of 8,439 mild Adverse events following immunization (AEFI) have been reported. These range from pain, swelling at the site of the inoculation, to body pains and nausea. 

“Similarly, 52 cases of moderate to severe incidents of AEFI have been reported. These presented as fever, vomiting, diarrhea headaches, dizziness and allergic reactions.

“Five states have the highest records of the AEFI namely: Kaduna (970) Cross River (859), Yobe (541), Kebbi (511), and Lagos (448),” he disclosed.

According to Shuaib, as of today, April 16th, 1,071,346, representing 53.2% of the eligible persons targeted with the AstraZeneca vaccine had been administered their first dose in this vaccination phase.

He said the data were based on reports received from states through the Electronic Management of Immunization Data (EMID) system only and did not take into account vaccinations that were not yet captured in the system.

“What this number means is that these are the people who have their information already uploaded on our data base, while others are awaiting upload, potentially due to network problems and the high traffic of those coming in to take their shots at the same time.

“While we continue to optimize our registration and immunization data system, we also encourage the state teams to deploy the most suitable internet service for their locations in order to speed up the data entry process, so that we can have the actual number of vaccinated people at any given time,” he said.

Shuaib added that in many states, the inoculation of frontline health workers had been completed and that they had begun offering vaccination to the elderly, particularly those that were 65 years and above.

“We are glad to be able to progress quickly offer immunization to more members of the community.

“Our rollout has been marked by safety, efficiency, best practice, and speed. The National Primary Health Care Development Agency (NPHCDA) and its development partners, have a platform of Senior Supervisors that engage in daily evening review meetings to determine the status of the COVID-19 vaccine implementation in all States & the FCT.”


AGENCY NEWS